Geode Capital Management LLC Cuts Stock Position in Renovaro Inc. (NASDAQ:RENB)

Geode Capital Management LLC lowered its holdings in Renovaro Inc. (NASDAQ:RENB) by 9.0% in the third quarter, HoldingsChannel reports. The firm owned 1,572,290 shares of the company’s stock after selling 155,995 shares during the quarter. Geode Capital Management LLC’s holdings in Renovaro were worth $760,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new position in Renovaro in the 2nd quarter valued at approximately $220,000. Rhumbline Advisers purchased a new position in Renovaro in the second quarter valued at $79,000. State Street Corp grew its stake in Renovaro by 3.8% during the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company’s stock worth $640,000 after purchasing an additional 48,114 shares in the last quarter. Finally, Barclays PLC increased its holdings in Renovaro by 315.7% during the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after purchasing an additional 52,804 shares during the period. 71.41% of the stock is owned by hedge funds and other institutional investors.

Renovaro Stock Performance

Shares of RENB opened at $0.79 on Friday. Renovaro Inc. has a 1 year low of $0.40 and a 1 year high of $5.25. The stock has a market capitalization of $125.77 million, a PE ratio of -0.83 and a beta of 0.65. The stock has a 50-day simple moving average of $0.97 and a 200-day simple moving average of $0.87.

Renovaro (NASDAQ:RENB) last issued its earnings results on Thursday, October 10th. The company reported ($0.45) earnings per share for the quarter.

Renovaro Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.